Torrent Pharmaceuticals has announced the reaffirmation of its long-term credit rating at [ICRA] AA+ (Stable) for banking facilities and existing Non-Convertible Debentures (NCDs). Additionally, a credit rating of [ICRA] AA+ (Stable) has been assigned for proposed NCDs. The company’s credit rating for its Commercial Paper programme remains at [ICRA] A1+.
Credit Rating Update
Torrent Pharmaceuticals has received updated credit ratings. The announcement was made on October 7, 2025.
Long-Term Credit Rating
The long-term credit rating for the company’s banking facilities and existing Non-Convertible Debentures (NCDs) has been reaffirmed at [ICRA] AA+ (Stable).
Rating for Proposed NCDs
A credit rating of [ICRA] AA+ (Stable) has been assigned to the company’s proposed Non-Convertible Debentures (NCDs).
Commercial Paper Programme
The credit rating for Torrent Pharmaceuticals’ Commercial Paper programme has been reaffirmed at [ICRA] A1+.
Source: BSE
